Cameco Gains 41.5% YTD: Should You Buy, Sell or Hold the Stock?

Cameco (CCJ) has significantly outperformed year-to-date, gaining 41.5% and trading above key moving averages, driven by maintained 2025 production targets despite a temporary JV Inkai suspension and an expected $170 million increase in Westinghouse's 2025 adjusted EBITDA from a Czech nuclear project. While the company is well-positioned for long-term growth amid rising nuclear energy demand and capacity expansion, its current valuation is considered premium (12.16x forward P/S vs. industry 1.24x) and uranium prices remain volatile, leading to a Zacks 'Hold' recommendation for new investors seeking a better entry point.

Analysis

Cameco (CCJ) has demonstrated significant market outperformance, with its stock gaining 41.5% year-to-date, substantially outpacing its industry (17.3%) and key peers. This rally is supported by bullish technicals, with the stock trading above its 50-day and 200-day simple moving averages. Fundamentally, the company has reinforced its operational stability by maintaining its 2025 production guidance of 22.4 million pounds despite a temporary Q1 shutdown at its Inkai joint venture. A key forward-looking catalyst is the expected $170 million increase in CCJ's share of Westinghouse's 2025 adjusted EBITDA, stemming from a new nuclear project in the Czech Republic, which enhances an already positive 6-10% five-year EBITDA growth outlook for the subsidiary. However, this positive operational and strategic picture is tempered by significant valuation concerns. CCJ trades at a forward price-to-sales ratio of 12.16, a steep premium to the industry's 1.24 and its own five-year median of 6.54. This is compounded by volatile uranium prices, which have declined 16.7% over the past year, and mixed analyst sentiment, with 2026 earnings estimates having been revised downward despite a near-term positive outlook for 2025.

Key Decisions for Investors

• Given the stock's 41.5% year-to-date run-up and stretched valuation, new investors should exercise caution and might consider waiting for a pullback or a clear stabilization in uranium spot prices before initiating a position.
• Existing shareholders should closely monitor the trajectory of 2026 earnings estimates, as recent downward revisions present a potential risk to the long-term growth narrative despite the strong 2025 outlook.
• Investors should factor the $170 million EBITDA uplift from the Westinghouse stake as a significant positive catalyst that partially justifies CCJ's premium valuation and differentiates it from pure-play uranium mining peers.